Planned intervention: On Thursday March 28th 07:00 UTC Zenodo will be unavailable for up to 5 minutes to perform a database upgrade.
Published May 23, 2021 | Version v1
Journal article Open

INVESTIGATION OF CLINICAL PARAMETERS OF PATIENTS ADMITTED WITH COVID-19 PNEUMONIA AND MEDICATIONS USED TO TREAT THEIR CO - MORBIDITIES

Description

There has already been further research into the risk factors and molecular mechanisms underlying Covid-19's serious breathing involvement and reservations regarding nonsteroidal anti-inflammatory inhibitors (NSAIDs) and renin angiotensin-aldosterone (RAAS) have also arisen.

Objective: The purpose of this study was to determine whether there were any associations between medications taken on a regular basis for comorbid diseases prior to the diagnosis of Covid-19 pneumonia and demographic or clinical characteristics at admission.

Materials and Methods: Between March 11th and April 15th, 2020, patients diagnosed with pneumonia in emergency, internal medicine, and cardiology outpatient clinics were recruited, and their clinical and demographic characteristics, including blood tests, oxygen saturations (SO2), and degree of lung infiltration on computed tomography, were analysed in relation to the medications they took on a regular basis.

Results: Angiotensin converting enzyme inhibitors (ACE inh.) or angiotensin receptor blockers (ARB) users were significantly older than the no-ACE inh./ARB group and had significantly lower SO2 levels on admission, whereas NSAID users with Covid-19 exhibited a significant female predominance and lower haemoglobin levels than the no-NSAID group. Additionally, PPI users had a significant female predominance, were older in age, and had lower haemoglobin levels. Finally, antiaggregant users who used Covid-19 had a lower SO2 level upon admission, and overall, cases involving regular drug use were significantly associated with older age.

Conclusion: There were significant associations between demographic and clinical characteristics at the time of admission for Covid-19 pneumonia and the use of major drug classes, including RAAS inhibitors, NSAIDs, and proton pump inhibitors.

Key words: Proton pump inhibitors, Non-steroidal anti-inflammatory drugs, Angiotensin receptor blockers, Angiotensin converting enzyme inhibitors, Covid-19.

Files

29.Investigation of Clinical parameters of patients admitted with Covid-19 pneumonia and medications used to treat their co - morbidities (1).pdf